LINC01014: LINC01014 is a long non-coding RNA (lncRNA) that has been implicated in various aspects of esophageal squamous cell carcinoma (ESCC) pathogenesis and drug resistance [PMC9031703]. It has been shown that LINC01014 is associated with the PI3K/Akt/mTOR pathway and is specifically involved in gefitinib drug resistance in ESCC [PMC9031703]. LINC01014 has been found to resist the efficacy of gefitinib, a targeted therapy, suggesting that it requires attention in terms of prognosis and therapy in clinical settings [PMC9031703]. Mounting evidence suggests that various lncRNAs, including LINC01014, are involved in ESCC chemotherapy resistance [PMC9031703]. Overexpression of LINC01014 has been shown to confer gefitinib resistance by inhibiting apoptosis through the PI3K/Akt/mTOR signaling pathway [PMC9031703]. Silencing the expression of LINC01014, on the other hand, promotes apoptosis induced by gefitinib treatment [PMC6991649]. The expression of LINC01014 can be determined using RT-qPCR with GAPDH as an internal control [PMC6991649]. It has also been found that overexpression of LINC01014 increases the expression of PIK3CA and Bcl-2 while decreasing the expression of Bax, suggesting its role in inhibiting apoptosis [PMC6991649]. In summary, LINC01014 is an lncRNA associated with drug resistance and modulation of the PI3K/Akt/mTOR pathway in ESCC. It plays a role in inhibiting apoptosis and altering sensitivity to gefitinib treatment.
Sequence features are shown above as colored rectangles. Zoom in and click to view details, or Reset
View annotations in different species by clicking on species names.
Scroll around to explore the entire tree. Click tree nodes to collapse or expand them. Hover over taxon names to display additional information.